Medtronic Plans $380 Million Purchase of Carotid Device Maker Contego
Medtronic plans to buy Contego Medical for $380 million, adding carotid and thrombectomy devices. Closing is expected in its fiscal third quarter.

Medtronic said on Nov. 16 that it intends to acquire Contego Medical, a privately held maker of devices for carotid artery disease and peripheral thrombectomy (removal of blood clots from vessels outside the heart). The deal is valued at $380 million, with potential payments after the acquisition. Medtronic expects to close it in the third quarter of its fiscal year, subject to customary closing conditions.
Medtronic, which is headquartered in Galway, Ireland, already sells Contego’s products in the United States. The companies first announced an exclusive U.S. distribution agreement in January 2025, and the acquisition builds on it.
What Medtronic is buying
The centerpiece is the Neuroguard IEP Direct System, which Contego recently received FDA approval for. According to the release, it is a system for transcarotid artery revascularization (TCAR), a procedure that restores blood flow through a narrowed carotid artery, with integrated embolic protection (a built-in way to catch debris) alongside flow reversal. The release calls it the first and only system of that kind.
The company reported results from the PERFORMANCE III study, a prospective, multicenter trial. At 30 days, the study recorded no strokes, no neurological deaths, no cranial nerve injuries and no myocardial infarctions (heart attacks) among patients treated with the device. These are findings the company presented in its own announcement, and its footnotes say outcomes should not be compared directly across studies.
The deal also covers Contego’s Excipio thrombectomy devices. Medtronic says they complement its Liberant thrombectomy system for peripheral vascular disease.
Why carotid disease matters
Carotid artery disease happens when the carotid arteries, the major vessels that supply blood to the brain, narrow or become blocked. Plaque can rupture or break loose and cause a stroke. The release says this accounts for about 20% of ischemic strokes. Treatments aim to reduce stroke risk, yet debris released during the procedure can itself add to the risk, which is the problem Contego’s embolic protection is designed to address.
Contego was founded by Ravish Sachar, MD, and Jay Yadav, MD. Its investors include Hatteras Venture Partners, U.S. Venture Partners, Lightstone Ventures and Amzak Health.
What it means for Medtronic’s financials
Medtronic expects the acquisition to be minimally dilutive to adjusted earnings per share (EPS) in FY27 and FY28, which means it should lower those figures slightly. After that, the company expects it to be neutral to accretive, meaning no effect on EPS or a boost to it. For Contego’s shareholders, the price is the $380 million figure, plus any payments that follow the closing.
David Moeller, who leads Medtronic Peripheral Vascular Health, said the company intends to become “an undisputed leader in carotid revascularization.” Linnea Burman, who leads Medtronic Neurovascular, said the purchase builds on the company’s commitment to reduce stroke risk. Sachar, Contego’s chief executive, called the deepened partnership the next chapter for his company and thanked its team, physicians, study sites and investors.
What to watch
The next milestone is the closing, which Medtronic expects in the third quarter of its fiscal year. The transaction remains subject to customary conditions until then.
Source: PR Newswire



